Salt Palace Convention Center, site of the 2018 BMT Tandem Meetings.

The 2018 BMT Tandem Meetings took place February 21-25 in Salt Lake City, Utah.

Promising results with expanded UCB product

Print Friendly, PDF & Email


2018 BMT Tandem Meeting
An expanded umbilical cord blood (UCB) product can produce favorable outcomes as a stand-alone graft, according to a presentation at the 2018 BMT Tandem Meetings. The product, MGTA-456, provided “rapid and durable” engraftment in patients with hematologic malignancies, according to John E. Wagner, MD, of the University of Minnesota... [Read Article]
Print Friendly, PDF & Email

Outcomes appear similar with MAC and RIC

Print Friendly, PDF & Email


Junichi Sugita, MD, PhD
New research suggests outcomes may be similar whether patients receive ­myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) prior to haploidentical peripheral blood stem cell transplant (haploPBSCT) with post-transplant cyclophosphamide (PTCy). Results from 2 parallel, phase 2 trials showed that MAC­-PTCy­-haploPBSCT and RIC­-PTCy-haplo­PBSCT produced comparable rates of engraftment, acute and... [Read Article]
Print Friendly, PDF & Email

HSCT approach provides ‘excellent’ survival in FA

Print Friendly, PDF & Email


Parinda A. Mehta, MD
A “risk-adjusted” approach leads to “excellent” survival in patients with Fanconi anemia (FA) undergoing alternative donor hematopoietic stem cell transplant (HSCT), according to a speaker at the 2018 BMT Tandem Meetings. All FA patients who received personalized doses of busulfan in place of total body irradiation (TBI) were alive... [Read Article]
Print Friendly, PDF & Email

Study confirms higher risk of infection with CB transplant

Print Friendly, PDF & Email


Amandeep Godara, MD
Results of a large, retrospective analysis support the notion that patients who receive cord blood (CB) transplants have a higher risk of infection than other hematopoietic stem cell transplant (HSCT) recipients. Investigators found that CB recipients had a significantly higher risk of bacterial, viral, and fungal infections in the early post-transplant... [Read Article]
Print Friendly, PDF & Email

Team identifies biomarkers for cGVHD in kids

Print Friendly, PDF & Email


2018 BMT Tandem Meetings
Researchers say they have identified prognostic biomarkers for chronic graft-vs-host disease (cGVHD) in children. The group found that recent thymic emigrants (RTEs) and regulatory T cells expressing CD31 and CD45RA (Treg RTEs) were significantly lower at day 100 after transplant in patients who developed cGVHD. Because prior research indicated that... [Read Article]
Print Friendly, PDF & Email

Expanded UCB product can stand alone

Print Friendly, PDF & Email


Mitchell Horwitz, MD
The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the 2018 BMT Tandem Meetings. Researchers found that a single NiCord unit provided “robust” engraftment in a phase 1/2 study of patients with high-risk hematologic malignancies. NiCord recipients had quicker... [Read Article]
Print Friendly, PDF & Email

Minihaplo-BMT can cure severe hemoglobinopathies

Print Friendly, PDF & Email


Javier Bolaños-Meade, MD
Cure of severe hemoglobinopathies is now possible for most patients, according to a speaker at the 2018 BMT Tandem Meetings. Results of a small study suggest that nonmyeloablative haploidentical bone marrow transplant (minihaplo-BMT), when used with 400 cGy total body irradiation and post-transplant cyclophosphamide, can cure sickle cell disease (SCD)... [Read Article]
Print Friendly, PDF & Email

Regimen deemed ‘safe and feasible’ in MM

Print Friendly, PDF & Email


Keren Osman, MD
A novel transplant regimen is “safe and feasible” for patients with multiple myeloma (MM), according to a presentation at the 2018 BMT Tandem Meetings. Researchers conducted a phase 1 trial investigating the addition of elotuzumab and autologous peripheral blood mononuclear cell (PBMC) reconstitution to standard autologous hematopoietic stem cell transplant... [Read Article]
Print Friendly, PDF & Email